Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging by improving signal intensity in T1‑weighted scans of the brain, spine, liver, cardiovascular system and vascular structures.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance (gadobenate dimeglumine) is used as a gadolinium‑based contrast agent to improve visualization in magnetic resonance imaging. - Brain MRI: enhances lesion detection and delineation. - Spine MRI: improves contrast of spinal cord and surrounding structures. - Liver MRI: provides better characterization of focal liver lesions. - Magnetic resonance angiography: increases vascular signal for clearer angiograms. - Cardiac MRI: facilitates assessment of myocardial perfusion and viability.

Adverse reactions to Multihance are generally related to its intravenous administration and the gadolinium chelate.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Injection site pain: transient discomfort at the infusion site. - Warmth sensation: brief feeling of heat or flushing during injection.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis: fibrotic skin changes in patients with severe renal impairment. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Acute kidney injury: rapid decline in renal function following exposure. - Cardiac arrest: rare but life‑threatening event. - Pulmonary edema: fluid accumulation in the lungs. - Severe hypotension: sudden drop in blood pressure.

When using Multihance, clinicians should observe several safety measures. - Renal function assessment: evaluate kidney function before use, especially in patients with eGFR <30 mL/min/1.73 m². - Pregnancy: category C, use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: consider discontinuing nursing or assess risk versus benefit. - History of allergic reactions: monitor for hypersensitivity during and after injection. - Concurrent gadolinium agents: avoid using multiple gadolinium contrast agents within 24 h. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other medicines or agents that affect renal function or cardiovascular response.

Major Interactions (Avoid): - Renal toxic agents: concurrent use with nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) may increase risk of NSF. - Other gadolinium agents: avoid administering another gadolinium‑based contrast within 24 h. - High‑dose iodinated contrast: may compound renal impairment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart‑rate response during stress MRI. - Diuretics: monitor fluid balance and renal function. - Chelating agents: may affect gadolinium clearance; observe for altered pharmacokinetics.